Prot #M23-716: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Program to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Severe Alopecia Areata

Project: Research project

Project Details

StatusActive
Effective start/end date3/20/24 → 3/20/27

Funding

  • AbbVie Inc. (Prot #M23-716)